Infectious Disease Therapeutics Market Report 2026

The infectious disease therapeutics market size has grown strongly in recent years. It will grow from $150.6 billion in 2025 to $160.84 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to high global burden of infectious diseases, widespread use of antibiotics and antivirals, government immunization programs, growth of pharmaceutical manufacturing capacity, increased funding for infectious disease research.

The infectious disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $200.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising antimicrobial resistance rates, increasing frequency of infectious disease outbreaks, expansion of global vaccination coverage, growing demand for novel antiviral therapies, stronger public health preparedness initiatives. Major trends in the forecast period include rising focus on antimicrobial resistance management, increasing development of broad-spectrum therapeutics, growing adoption of combination drug therapies, expansion of rapid-response therapeutics for outbreaks, increased investment in vaccine research and stockpiling.

The rising prevalence of infectious diseases is expected to drive the growth of the infectious disease therapeutics market in the coming years. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, parasites, or prions. Factors contributing to the increasing prevalence of infectious diseases include climate change and environmental disruption, antimicrobial resistance, weakened immune systems, greater human-animal interactions, and ecological disturbances. Infectious disease therapeutics are critical for treating infections, reducing morbidity and mortality, and controlling the spread of communicable diseases within communities and across populations. For example, in October 2023, the UK’s National Health Service (NHS) England reported that in 2022/23, hospitals recorded 147,285 admissions with a primary diagnosis of urinary tract infection (UTI). Patients over 65 accounted for 56% of these cases (82,392 admissions), with the 80-84 age group having the highest number at 17,280 admissions. Therefore, the increasing prevalence of infectious diseases supports the growth of the infectious disease therapeutics market.

Key companies in the infectious disease therapeutics market are focusing on multispecific antibody platforms, such as the multispecific therapeutic antibody reactor (MSTAR), to enhance efficacy, broaden protection, and strengthen responses to emerging viral threats. MSTAR is an advanced multispecific antibody technology that integrates several independent binding regions into a single therapeutic molecule, allowing broad viral neutralization, simultaneous targeting of multiple epitopes, and rapid adaptation to new variants. For instance, in September 2023, ModeX Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, secured a contract from the Biomedical Advanced Research and Development Authority to advance its multispecific antibody candidates for the treatment and prevention of viral infectious diseases, including COVID-19 and influenza. These candidates offer broad activity against circulating viral strains, potential compatibility with gene-based delivery using mRNA or DNA vectors, and a multi-binding site architecture. This multispecific antibody approach enhances therapeutic outcomes by shortening development timelines, expanding protective coverage, and reducing the complexity associated with combination biologic treatments.

In June 2023, Shionogi & Co., Ltd., a Japan-based pharmaceutical company, acquired Qpex Biopharma Inc. for an undisclosed amount. Through this acquisition, Shionogi aims to strengthen its infectious disease therapeutics portfolio by integrating Qpex’s advanced pipeline, including xeruborbactam, a first-in-class β-lactamase inhibitor targeting multidrug-resistant bacterial infections. Qpex Biopharma Inc. is a US-based clinical-stage biotechnology company specializing in developing novel antimicrobial treatments for serious and drug-resistant infectious diseases.

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, AstraZeneca, Novartis International AG, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceuticals, Moderna Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioCryst Pharmaceuticals Inc.

North America was the largest region in the infectious disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infectious disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the infectious disease therapeutics market by increasing costs of active pharmaceutical ingredients, biologics manufacturing inputs, and vaccine production materials. These impacts are most pronounced across drug and vaccine segments, particularly in asia-pacific and europe where cross-border sourcing of raw materials is significant. Higher tariffs have raised production and procurement costs for pharmaceutical companies and healthcare providers. However, tariffs are also encouraging domestic drug manufacturing, supply chain diversification, and strategic investments in local vaccine production, strengthening long-term market resilience.

The infectious disease therapeutics market research report is one of a series of new reports that provides infectious disease therapeutics market statistics, including infectious disease therapeutics industry global market size, regional shares, competitors with a infectious disease therapeutics market share, detailed infectious disease therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease therapeutics industry. This infectious disease therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Infectious disease therapeutics encompass treatments and interventions designed to combat illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. The primary aim of these therapeutics is to eliminate the infectious agent from the body or control its replication and spread, thereby reducing symptoms, preventing complications, and supporting recovery.

The main categories of infectious disease therapeutics include drugs and vaccines. Vaccines are biological preparations that stimulate the immune system to recognize and combat specific infectious agents. These therapeutics target a range of diseases, including tuberculosis, HIV/AIDS, influenza, hepatitis, and others, and are utilized by various end users such as hospitals and clinics, retail pharmacies, research organizations, and additional healthcare and scientific institutions.

The infectious disease therapeutics market consists of sales of antibiotics, antivirals, and immunotherapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.